A Structure-Based Approach to Ligand Discovery for 2C-Methyl-d-erythritol-2,4-cyclodiphosphate Synthase: A Target for Antimicrobial Therapy†

The nonmevalonate route to isoprenoid biosynthesis is essential in Gram-negative bacteria and apicomplexan parasites. The enzymes of this pathway are absent from mammals, contributing to their appeal as chemotherapeutic targets. One enzyme, 2C-methyl-d-erythritol-2,4-cyclodiphosphate synthase (IspF), has been validated as a target by genetic approaches in bacteria. Virtual screening against Escherichia coli IspF (EcIspF) was performed by combining a hierarchical filtering methodology with molecular docking. Docked compounds were inspected and 10 selected for experimental validation. A surface plasmon resonance assay was developed and two weak ligands identified. Crystal structures of EcIspF complexes were determined to support rational ligand development. Cytosine analogues and Zn2+-binding moieties were characterized. One of the putative Zn2+-binding compounds gave the lowest measured KD to date (1.92 ± 0.18 μM). These data provide a framework for the development of IspF inhibitors to generate lead compounds of therapeutic potential against microbial pathogens.

[1]  W. Hunter,et al.  The structure of Mycobacteria 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase, an essential enzyme, provides a platform for drug discovery , 2007, BMC Structural Biology.

[2]  William N. Hunter,et al.  The Non-mevalonate Pathway of Isoprenoid Precursor Biosynthesis* , 2007, Journal of Biological Chemistry.

[3]  Terry K. Smith,et al.  Structure and reactivity of LpxD, the N-acyltransferase of lipid A biosynthesis , 2007, Proceedings of the National Academy of Sciences.

[4]  P. Hajduk.  Fragment-based drug design: how big is too big? , 2006, Journal of medicinal chemistry.

[5]  A. Holý.  Antiviral acyclic nucleoside phosphonates structure activity studies. , 2006, Antiviral research.

[6]  A. Dmoszyńska,et al.  Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG) , 2006, Annals of Hematology.

[7]  F. Diederich,et al.  Fluorescent inhibitors for IspF, an enzyme in the non-mevalonate pathway for isoprenoid biosynthesis and a potential target for antimalarial therapy. , 2006, Angewandte Chemie.

[8]  Robin Taylor,et al.  Comparing protein–ligand docking programs is difficult , 2005, Proteins.

[9]  N. Ramsden,et al.  A double mutation of Escherichia coli2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase disrupts six hydrogen bonds with, yet fails to prevent binding of, an isoprenoid diphosphate. , 2005, Acta crystallographica. Section F, Structural biology and crystallization communications.

[10]  T. Borza,et al.  Multiple Metabolic Roles for the Nonphotosynthetic Plastid of the Green Alga Prototheca wickerhamii , 2005, Eukaryotic Cell.

[11]  B. G. Rao,et al.  Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. , 2005, Current pharmaceutical design.

[12]  W. Eisenreich,et al.  Hexameric Assembly of the Bifunctional Methylerythritol 2,4-Cyclodiphosphate Synthase and Protein-Protein Associations in the Deoxy-xylulose-dependent Pathway of Isoprenoid Precursor Biosynthesis* , 2004, Journal of Biological Chemistry.

[13]  Wolfgang Eisenreich,et al.  Biosynthesis of isoprenoids: a bifunctional IspDF enzyme from Campylobacter jejuni. , 2004, European journal of biochemistry.

[14]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[15]  Gerhard Klebe,et al.  Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding mode detected by crystal structure analysis. , 2003, Journal of medicinal chemistry.

[16]  Jochen Wiesner,et al.  Fosmidomycin for malaria , 2002, The Lancet.

[17]  D Spruce,et al.  Automation of the collection and processing of X-ray diffraction data -- a generic approach. , 2002, Acta crystallographica. Section D, Biological crystallography.

[18]  E. Eisenstein,et al.  Structure of 2C‐methyl‐D‐erythrol‐2,4‐cyclodiphosphate synthase from Haemophilus influenzae: Activation by conformational transition , 2002, Proteins.

[19]  Charles S Bond,et al.  Structure of 2C-methyl-d-erythritol 2,4- cyclodiphosphate synthase: An essential enzyme for isoprenoid biosynthesis and target for antimicrobial drug development , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  H. Seto.  Faculty Opinions recommendation of Structure and mechanism of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase. An enzyme in the mevalonate-independent isoprenoid biosynthetic pathway. , 2002 .

[21]  S. Steinbacher,et al.  Structure of 2C-methyl-d-erythritol-2,4-cyclodiphosphate synthase involved in mevalonate-independent biosynthesis of isoprenoids. , 2002, Journal of molecular biology.

[22]  W. Eisenreich,et al.  The non-mevalonate pathway of isoprenoids: genes, enzymes and intermediates. , 2001, Current opinion in chemical biology.

[23]  J Navaza,et al.  Implementation of molecular replacement in AMoRe. , 2001, Acta crystallographica. Section D, Biological crystallography.

[24]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[25]  B Wieland,et al.  Identification of novel essential Escherichia coli genes conserved among pathogenic bacteria. , 2001, Journal of molecular microbiology and biotechnology.

[26]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[27]  Gerhard Klebe,et al.  Subnanomolar Inhibitors from Computer Screening: A Model Study Using Human Carbonic Anhydrase II. , 2001, Angewandte Chemie.

[28]  W. Doolittle,et al.  The role of lateral gene transfer in the evolution of isoprenoid biosynthesis pathways , 2000, Molecular microbiology.

[29]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[30]  W. Eisenreich,et al.  Biosynthesis of terpenoids: YgbB protein converts 4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate to 2C-methyl-D-erythritol 2,4-cyclodiphosphate. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Klebe,et al.  Knowledge-based scoring function to predict protein-ligand interactions. , 2000, Journal of molecular biology.

[32]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[33]  R. Ridley.  Planting the Seeds of New Antimalarial Drugs , 1999, Science.

[34]  H. Lichtenthaler,et al.  Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. , 1999, Science.

[35]  S. E. D. Laszlo,et al.  Carbohydroxamido-oxazolidines: antibacterial agents that target lipid A biosynthesis. , 1999, Bioorganic & medicinal chemistry letters.

[36]  C. Fierke,et al.  UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase of Escherichia coli is a zinc metalloenzyme. , 1999, Biochemistry.

[37]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[38]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[39]  G. Kleywegt.  Use of non-crystallographic symmetry in protein structure refinement. , 1996, Acta crystallographica. Section D, Biological crystallography.

[40]  J. Schwender,et al.  Biosynthesis of isoprenoids (carotenoids, sterols, prenyl side-chains of chlorophylls and plastoquinone) via a novel pyruvate/glyceraldehyde 3-phosphate non-mevalonate pathway in the green alga Scenedesmus obliquus. , 1996, The Biochemical journal.

[41]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[42]  H. Sahm,et al.  Isoprenoid biosynthesis in bacteria: a novel pathway for the early steps leading to isopentenyl diphosphate. , 1993, The Biochemical journal.

[43]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[44]  W. Eisenreich,et al.  The identification of isoprenoids that bind in the intersubunit cavity of Escherichia coli 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase by complementary biophysical methods. , 2005, Acta crystallographica. Section D, Biological crystallography.

[45]  S. Yokoyama,et al.  Structure and catalytic mechanism of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (MECDP) synthase, an enzyme in the non-mevalonate pathway of isoprenoid synthesis. , 2003, Acta crystallographica. Section D, Biological crystallography.

[46]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[47]  S. Sauret-Güeto,et al.  Escherichia coli engineered to synthesize isopentenyl diphosphate and dimethylallyl diphosphate from mevalonate: a novel system for the genetic analysis of the 2-C-methyl-d-erythritol 4-phosphate pathway for isoprenoid biosynthesis. , 2001, The Biochemical journal.

[48]  M. Rohmer,et al.  CO2 as main carbon source for isoprenoid biosynthesis via the mevalonate-independent methylerythritol 4-phosphate route in the marine diatoms Phaeodactylum tricornutum and Nitzschia ovalis. , 2000, Phytochemistry.

[49]  M. Rohmer.  The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants. , 1999, Natural product reports.

[50]  J. Porter,et al.  Biochemistry of polyisoprenoid biosynthesis. , 1976, Annual review of biochemistry.

[51]  B. Ed,et al.  Biochemistry of Polyisoprenoid Biosynthesis , 1976 .